Studies on the influence of esterase inhibitor to the pharmacokinetic profiles of oseltamivir and oseltamivir carboxylate in rats using an improved LC/MS/MS method

Biomedical Chromatography

Volumn 23, Issue 8, 2009, Pages 852-857

  Chang, Qi ^a,b   Chow, Moses S S ^b,c   Zuo, Zhong ^b  

^a INSTITUTE OF MEDICINAL PLANT DEVELOPMENT   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Dichlorvos; LC MS MS; Oseltamivir; Oseltamivir carboxylate; Pharmacokinetics

Indexed keywords

BODY FLUIDS; CARBOXYLATION; ENZYMES; ESTERS; PHARMACOKINETICS;

DICHLORVOS; ETHYL ESTERS; LC-MS-MS; LC.MS/MS; OSELTAMIVIR; OSELTAMIVIR CARBOXYLATE; PHARMACOKINETIC PROFILES; PLASMA CONCENTRATION; PLASMA SAMPLES; RAT PLASMA;

RATS;

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; CEFALEXIN; DICHLORVOS; ESTERASE INHIBITOR; FORMIC ACID; METHANOL; OSELTAMIVIR;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG STRUCTURE; EX VIVO STUDY; HYDROLYSIS; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; RAT; SENSITIVITY AND SPECIFICITY; SPRAGUE DAWLEY RAT; STANDARD; TIME TO MAXIMUM PLASMA CONCENTRATION;

AVES; RATTUS;

EID: 70349512947     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1195     Document Type: Article

References (14)

1. Abe M, Smith J, Urae A, Barrett J, Kinoshita H and Rayner CR. Pharmacokinetics of oseltamivir in young and very elderly Japanese subjects. The Annals of Pharmacotherapy. 2006; 40: 1724-1730.
2. Bahrami G, Mohammadi B and Kiani A. Determination of oseltamivir carboxylic acid in human serum by solid phase extraction and high performance liquid chromatography with UV detection. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 864: 38-42.
3. Eisenberg EJ, Bidgood A and Cundy KC. Penetration of GS4071, a novel influenza neuraminidase inhibitor into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104. Antimicrobial Agents and Chemotherapy 1997; 41: 1949-1952.
4. He G, Massarella J and Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clinical Pharmacokinetics 1999, 37: 471-484.
5. Lindegardh N, Davies GR, Tran TH, Farrar J, Singhasivanon P, Day NP and White NJ. Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases. Antimicrobial Agents and Chemotherapy 2006; 50: 3197-3199.
6. Lindegardh N, Hanpithakpong W, Wattanagoon Y, Singhasivanon P, White NJ and Day NP. Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of oseltamivir and its metabolite oseltamivir carboxylate in plasma, saliva and urine. Journal of Chromatography B 2007; 859: 74-83.
7. Massarella JW, He GZ, Dorr A, Nieforth K, Ward P and Brown A. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers. Journal of Clinical Pharmacology 2000; 40: 836-843.
8. McClellan K and Perry CM. Oseltamivir: a review of its use in influenza. Drug 2001; 61: 263-283.
9. Oo C, Barrett J, Hill G, Mann J, Dorr A, Dutkowshi R and Ward P. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children. Paediatric Drugs 2001; 3: 229-236.
10. Oo C, Hill G, Dorr A, Liu B, Boellner S and Ward P. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years. European Journal of Clinical Pharmacology 2003; 59: 411-415.
11. Quon CY, Mai K, Patil G and Stampfli HF. Species differences in the stereoselective hydrolysis of esmolol by blood esterases. Drug Metabolism and Disposition 1988; 16: 425-428.
12. Schentag JJ, Hill G, Chu T and Rayner CR. Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects. Journal of Clinical Pharmacology 2007; 47: 689-696.
13. Sweeny DJ, Lynch G, Bidgood AL, Lew W, Wang KU and Cundy KC. Metabolism of the influenza neuraminidase inhibitor prodrug oseltamivir in the rat. Drug Metabolism and Disposition 2000; 28: 737-741.
14. Weltshire H, Wiltshire B, Citron A, Clarke T, Serpe C, Gray D and Gerron W. Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir in human and animal plasma and urine. Journal of Chromatography B 2000; 745: 373-388.